Solobacterium moorei 敗血症の1例 : 本邦初の報告症例と菌株の特徴について

全文

(1)Title. Solobacterium moorei 敗血症の1例 : 本邦初の報告症例と菌株の特徴について( 本文(Fulltext) ). Author(s). 森, 早苗; 渡, 智久; 安田, 篤志; 三浦, 佐知子; 尾栢, 隆; 畑中, 宗博; 大楠, 清文. Citation. [日本臨床微生物学雑誌 = The journal of the Japanese Society for Clinical Microbiology] vol.[18] no.[4] p.[236]-[244]. Issue Date. 2008-12-25. Rights. The Japanese Society for Clinical Microbiology (日本臨床微生物学会). Version. 出版社版 (publisher version) postprint. URL. http://hdl.handle.net/20.500.12099/33985. ※この資料の著作権は、各資料の著者・学協会・出版社等に帰属します。.

(2) ῌ)¤¥¦Q§¼ 2008. 236. ῌ῎. ῑ῍. Solobacterium moorei 1 .

(3) 1)

(4) . 1)

(5) 1)

(6) 1)

(7) 1) 2). . 1)

(8) 1)

(9) 2). . !. "#!$%. "&' 20 ( 6 # 23 )*+$ &' 20 ( 8 # 18 )*,%. -.&'.()*/.0+,- Solobacterium moorei .-/012341 /5-6 72893:4;56+<. 7=89:>.;</=? 3 60 @>.. +,-6 40A?@BAC/BCDDEFE/*F2$ GGH9HIJ36 H KLMNO3PIJ+IJ 2 )Q&'RST.U$ KV./W5()*/.0 Prevotella melaninogenica X$LNO36 ()*/.08$ MNYZS RapID ANAII, API 20A +[ Eggerthella lenta ONNO36 2\2$ $L8]^)_àbSc.$ P defghi[c. E. lenta EQj.58kIJ 33?RS2 5 -1/TU236 l1+ 16S rRNA mVenWXoN23pq$ Solobacterium moorei nY 99.6r ZM.+,J31\sRMNNO36 t[NO -MNYZS u_^v_b S. moorei 8\]

(10) ^wNO I 3?$ _+1R/MN5-1 8x`+,-6 2\2IXs$ yMNNO-za.X,- E. lenta 8bcd e{Xk I-|\$ a-glucosidase X E. lenta 8c.+,-}f$ S. moorei 8/.,-1Xg2/ ~h5-+ij+,-1/ks\236 )l $ Q[72m/$ n2IXs$ V6$ MNYZSe{.I /op2 $ .UqIMNpq/ r2 3 6 Key words: Solobacterium moorei$ $ KV.$ 16S rRNA, Eggerthella lenta. ῏. ῒ. 3+5-6. Solobacterium moorei 8$ 2000 ( Kageyama s1) .J s3It.R2 rNO3.&'.()*/.0+,-6 $ S. moorei 8 Solobacterium t+u}R+,-6 S\s8v w1) |\$ 1$ [xyz2), 3) \s$LNO. ῐΐ 72 60 @$ >.6 ¡~ $ ¢£a¤$ 93:$ :>.< 7=89;<6 HK". "8"¥. -6 S. moorei XPIJ\s$LNO3_b8$. 40A$ ^;¦ 72 mmHg$ § ;¦ 44 mmHg. {+ 3 X46) NO -+$ . . 75/$+,J36 HKPu_^. 23U+8$ X4+8=? I 6 $. /y 1 W5¨ WBC 2.33©103 /ml /W2$. OO8+? PIJ\s S. moorei /$. CRP 8 17.39 mg/dl ª «e{XsO36. L2$ .5/|23Q$ }I/. 1|\8¢£a¬£a[=X=?sO36 ~ 2002 (D 93:FNO$ . 2 (·090῍8666) ¸ t 6 ¡¢ 2῍1 .

(11) TEL: 0157῍24῍3115 1£ 1258 FAX: 0157῍22῍3339 E-mail: t῎[email protected]. 16 )¤¥¦Q§º». Vol. 18. No. 4. 2008.. ®/LM23¨ 2005 ($ ¯?3?93 LM6 lQ$ j3?H/°U2. 3X$ 2006 ( 11 #<. 7=:>/=?$ H3. /±2 7²/V'236 lQ8$ ³T ´+µ,/23¶®/LM2. 3¨ 2007 ( 1 # 31 ) 40A?@BAC/BC.

(12) Solobacterium moorei 6&7 1 { z 1

(13) &'78QRS Peripheral blood 2.85º106/ml 10.3 g/dl 29.2~. RBC Hb Ht WBC Seg Lym Mono Eosino Baso Plt. 2.33º103/ml 83.4~ 8.4~ 3.0~ 2.7~ 0.7~ 272º103/ml. Blood chemistry TP AST ALT LD Total-Bill UN Cr Na K Cl CRP. 5.8 g/dl 59 IU/L 55 IU/L 160 IU/L 0.3 mg/dl 22.6 mg/dl 0.8 mg/dl 130 mEq/L 3.8 mEq/L 87 mEq/L 17.39 mg/dl. 237. ghi?N0O2n* P"oQpR 3 @1S1T8qroQK _shR1 ;t J` ( 2). . 2 ?@ 93F AB9YZ[\]^ AB'uUV vWGH + ]wx yzR{|} II 5~ &'XV _TSA : BD` BY y U Y R ] X V _BYCHO : BD` BTB XV _BTB : BD` ABHK X V _ABHK Y J ` NV ABHK X V _NVABHK YJ` :3; BBE XV _BBE : BD` a9L ^yR( Z

(14) L TSA

(15) BYCHO 35G 7~ CO2.

(16) . BTB 35G X B F L ABHK

(17). . NVABHK }ABVWy9 _[lm.

(18)

(19) . !"#$ %. ][` 9>L 35G AB#JH 3). . & ' " ( ) $ % * + pazufloxacin. ^yR L ABHK )cghi?. 1,000 mg/day 7 ,

(20) micafungin 50 mg/day 16. N0\]R >L ShR{]. ,"-.$ /0 7 12 cefo-. _;tJ` TR{] _sQ. zopran 1 g/day 7 , 14 34 cefpirome 1 g/. TR{] lm` :3;}[R^{]. . day 5

(21) 6$ &'78 %9. _RID Zyme IND-S {] [lmsQ[{` . 1 7 :3; 8 < 3 =($ >?@. ( ^_V] RapID ANAII _i`. AB0

(22) 0"7!$ ". API 20 A _ : s w R` : 3 ; CRYSTAL. C

(23) # $D%E" F%@& 1 '. ANR _: BD` a9 ¡`# 0U#_. 40G(%)*"H4 CRP +@ % 9 . 16S rRNA ¢a£¤¥bcd^7¦

(24) §e¨f. 23 mg/dl IJ,- &K% .L/'0. 3 ghi©N0 >L ShR. 1")" &KM2@N2? 16 . {]

(25) RapID ANAII 9>L0Uª_. 2 O 15 P3$. 4). . Pg0« MIC +h_ h}xYR] ¬ 1.. .

(26) 4$5N:3;&'78QRS1 26&7TUVW

(27) 8$ /0( &' "()$ 92F XB9YZ[\]. _lm`

(28) ^®h{ _lm` a9 35G 48

(29) ,AB% MIC +T_ ) 5). S. moorei Eggerthella lenta ATCC . !". ^

(30) 93F AB9YZ[\]^ _>?@: BD` . P g 0 « ^ _ i ¯ ( ° RapID. 9> ;<&'=> BACTEC 9120 _:. ANAII

(31) API 20A J0Uj

(32) Lk 1 ±l H. BD` a9 2 AB9YZ[\]^. " E. lenta 0« ATCC43055 m 0. b"?@" XB9YZ[\]^ 7 . p n

(33) u U ^ _ V ] ¥ o p ² > L S.. IJ0)cE 1. moorei _Pg0«`

(34) q³7r) s0«. 2..

(35). ABHK J 48

(36) ,AB% 7r 9> 0. 1). . pnq³ghiK _Bartholomew & Mittwer. BACTEC9120 J?@ 93F AB9YZ[. 1` 34)> ^_V] RapID ANAII API. \]ÂB'CDd LE0# eF GHI. 20A :3; CRYSTAL ANR a9 0't. :fJ ghiK Bartholomew & Mitt-. ' Z:3;T_

(37) , úV]Fµu. wer 1 _jRkR M K LMlm` J) $2. vw¶· x¸L( E. lenta ¥x«y¹ : \|}m¼~. Vol. 18. No. 4. 2008. 17.

(38) « ¬. 238. A1. ®¯°!"±²³´µ#¶. $%·&¸'¹(. fcde& ! A&892:;9$J $%&'(V$23 @ B (¡ G\ A&¢£ N#¤?1=9$G\ @Bartholomew & Mittwer ¥1,000B.

(39) 3.. . 1). . . !"# $%&'()*+,-./. 012345067&829:; 9$<=9$(>?1 @A 1B 9$C DEF 2). ! =9GE. . TSA BYCHO BTB H & IJ6KE LM

(40) 48 NOP9$< =9$& 2 Q&RSTU(JV1 9$ ABHK &WXY 1 mm &Z! [;\]RSTU< I @A 2B =9 $ ABHK < NVABHK ^!&H 2_ ( BBE IJ6KE à 2 Q&b$. cde

(41) f&. A2. Solobacterium moorei &RSTU¦g @LM

(42) 48 NO ABHK §¨

(43) ©B. !gh?1$23<. 'i . 78.9wB <v?1r CRYSTAL ANR v>. 3)

(44) . (z{ |9}(GE x RapID ANAII. 9$&j*Uklmd )n/oUk. < API 20A &v~KV E. lenta <. lmd pUelmd ;q =9GEr. j*Uklmd(=9G\<4

(45) . RapID ANAII sStueRUp( 020041, . (=9G\< ' 6 E. lenta &. v > 91.3w Eggerthella lenta (Wade et al.,. 90< (V1 1V&~KV . 1999)7) <v?1 x API20A E. lenta. $Q&vV6KE . @sStueRUpy 00000002, v> 94.2wB. #\$Q&v $& 16S. <6E( CRYSTAL ANR Atopobium minu-. rRNA &( S. moorei & (JCM. tum @sStueRUpy 2233470000 v>. 10645T) &1< 99.6w 'i \<(KE. 18 )*+º,»¼ Vol. 18. No. 4. 2008..

(46) Solobacterium moorei §¨© 1 ª T 2 yz$% Solobacterium moorei LMNO ,PQRS. 239. mg/ml( sparfloxacin ? 0.25 mg/ml ZZ[XU ?( \LM.W#]^_` MIC XY. Antimicrobial agent. MIC (mg/ml). ab cde BC cefozopran MIC X. Ampicillin Penicillin G Piperacillin Cefmetazole Ceftizoxime Cefozopran Flomoxef Imipenem Amoxicillin/clavalanic acid Clindamycin Minocycline Chloramphenicol Sparfloxacin. 0.06 0.06 0.5 0.5 0.5 0.5 0.5 0.12 0.18 0.06 0.12 4 0.25. LMNO,g.( sparfloxacin ? 2 mg/ml h. 0.5 mg/ml _`fXU P. melaninogenica ,U?( ijLM k

(47) .Vl NO ,Yab 5). S. moorei

(48) Eggerthella lenta ATCC

(49) . )*m2 6n!opqY. E. lenta ?r& <)*s,tuvw-! pq$%n x ( S. moorei Hyz!K .{,UV)*s, tuv-!Yab H| 3K }( #~; ,.( RapID ANAII Y( S. moorei ? arginine, serine 67 a-glucosidase s,U( E. lenta . arginine serine ? s , Y a b ?( a-gluco-.

(50) S. moorei . sidase .+,YabA RapID ANAII C

(51) .

(52) . !"#. yz! E. lenta ATCC < . $% &'( )*+,-!.( /012( BBE. RS1), 6), 8) $%

(53) n S. moorei . 345 6789:;+,<=,>. ,> T 3 UVA API 20A

(54) .(. Prevotella melaninogenica ? @ # $ % A RapID. S. moorei E. lenta YVl . ANAII B C ! " D E F G( P.. F<b E. lenta ATCC .( . melaninogenica H#EI 99.9JK #$%. C

(55) 6nPQY.s,<. 4). . ( E. lenta. ,>UA CRYSTAL ANR. S. moorei !LMNO,PQRST 2 U. Y.( S. moorei E. lenta ATCC Y,. V W#LM MIC XY chloramphenicol ? 4.

(56) ?F%( arginine, serine, glycine, ala-. |3. Solobacterium moorei (A) Eggerthella lenta ATCC43055 (B) )*m2 S. moorei .! &¡?¢£¤Zw->

(57) b{,UV &'( E. lenta .r&<->U

(58) n HBartholomew & Mittwer ( ¥1,000K. «. ¬® ¯°±. Vol. 18. No. 4. 2008. 19.

(59) ± ?@²A. 240. B³²ĆDµ²5¶·E²F¸. G²HI¹J²0KLM. > 3 !"/ Eggerthella lenta ATCC43055 RapID ANAII .«;/R0=> ?8 Results Isolate. E. lenta ATCC43055. Published S. moorei straina. ® ® ® ® ¯ ® ® ® ® ® ® ® ® ® ¯ ¯ ® ® ® ®. ® ® ® ® ® ® ® ® ® ® ® ® ® ® ¯ ¯ ® ® ¯ ¯. ® NT ® ® ¯ ® ¯ ® ® NT NT NT ¯ NT ¯ NT NT ® ® ®. Biochemical reaction or enzyme. Urease p-Nitrophenyl-b,9-disaccharide (b-Disaccharidase) p-Nitrophenyl-a,A-arabinoside (a-Arabinosidase) o-Nitrophenyl-b,9-galactoside (b-Galactosidase) p-Nitrophenyl-a,9-glucoside (a-Glucosidase) p-Nitrophenyl-b,9-glucoside (b-Glucosidase) p-Nitrophenyl-a,9-galactoside (a-Galactosidase) p-Nitrophenyl-a,A-fucoside (a-Fucosidase) p-Nitrophenyl-n-acetyl-b,9-glucosaminide (N-Acetyl-glucosaminidase) p-Nitrophenylphosphate Leucyl-glycine-b-naphthylamide Glicine-b-naphthylamide Proline-b-naphthylamide (Proline arylamidase) Phenylalanine-b-naphthylamide Argnine-b-naphthylamide (Arginine dehydrogenase) Serine-b-naphthylamide Pyrrolidonyl-b-naphtylamide Indole production Nitrate reduction Catalase a. NT: not tested. nine, pyroglutamic acid, lysine, methionine, phen-. 7/.@A sg4 7P.'tuv. ylalanine, leucine

(60) . wx y $ (z{9E&' ?Z0 | j}~ Va #$R)* E. lenta. ῌ. ῍. /<+BA7/ , 740?.<. . !" #$ 2 % &'. #$() *+ ,#- . E. lenta /012. - . A!% 4pV.@ 4/ /0> 1v 2 l*+ Solobacterium moorei / )!%<%. 34056

(61) .7!%.8 91. &'E3VV <. : ;6< 2 3 => ? 297. $#0# 21$ ;4uv.<7!%. /.@A B0CD &' #$ Eubacte-. BA7/<Ci$5.@A - -. rium !E F!% GBAH<

(62) B. . A!%<6.@17/<(.. IJ #7/EK 2L#0M N O#. @A2 7 .72;4.<0#? 2Z. $ P4Q 2@A R E. lenta <!SE. $ uv. S. moorei @A#<B. TUVWX 1$=> ?2Y0A/#4. A7/<.0#/]^. 89) R9Z7/ &'Z.. l7. S. moorei / E. lenta ? 8u9B. <[\2@A/]^: 6< E. lenta <_U. A 1: API 20A / CRYSTAL ANR .< Bp. àbEcde. b

(63) B7/2#10). $IJ.K

(64) i:!% GBA7. !"< chloramphenicol / sparfloxa-. /<.01 E. lenta I" ¡¢£¤¥x. . cin MIC !f"gh #iAZ. _Uà. 2 API 20A .<¦ . §*7.< .@1. bjEcde. $<$k0 MIC !. 7*+< &' m¨ $<#©0#.

(65) l $56

(66) < mn %o.. 7/ ª^ l«;2!%)* ?.<0#¬. E. lenta <Bp$ q;0&!?/ $Xr. < §*7 A<ª¥x/-#2=.@A7/. bj. 20 ')NºOP>»¼ Vol. 18. No. 4. 2008..

(67) Solobacterium moorei m?> 1 V. 241. RapID ANAII

(68). EaRghi . S. moorei a-. !"E0j klQ m?. glucosidase E. lenta . > % h % S S.. a-glucosidase CRYSTAL. moorei n$# S3 #$ $. ANR . !"#$ RapID ANAII %. 33. UE[[xopq#$% >6M. #&'(

(69) )'* +,-($#$ . $ [[x klQ m?>. CRYSTAL ANR &'(

(70) ).'/01%. rstnNMrs%. . %^. #$ 2$3 S. moorei CRYS-. u' S. moorei ?@3Dvw. TAL ANR 3%4. /` 3 V [[x \ ". 56 789 S. moorei : ;. ab>V. %# RapID ANAII <= a-glucosidase. SI|GHQyy>w ?@. %>6. 3Dv. ?@.ABCD#EF 4 3GHIJKL0 N OE . " P EQ. M #$. hS jkEx. S. moorei = Mz{E %. N |} ¡~ 4¢ < 3 >V< $#. E0 16S rRNA £¤. R#';#$. " RS QTE!"UV. S. moorei cd, " UE0. 3 Eubacterium #E $%Q .AB. 0%# X3!" =. E%#%%W&11) . ho%# xDZ N $. 'X() EQY% N. E0 ?@y@ zEQ DZ¥3!". 3 *DZ+ ?@ .AB. $]^ xE%%. ,%[-\./. #^¦ Z% $w%>6. % N]^. xTE%. E01234_/`#$ 3 . " ab>V. abcd, ,3E0 e5 . #§#$: N $ ?@3. RS E. lenta %. 34fg1_h./6i% N . DvTE$# |Y ¨w. ?@3jkE!"78 ?@. w abRS I|}Q EQ. D9S 0.5l13m % RS!". .ABEw© GH. 78:n$o%# ;<<=[-\=. JKL}% #$ $3> S. moorei. 2 jkERE?> p?<Rq. :. TEDZ+@rs%AB. . rK#DZw% . 12) *t<= 2007 C 7 ul2008 C 3 u' ;?@ 173 vD9Sjk. ῌ. E!" 15 v D 9mEw#$. ab ?@.AB . ῍. hM FxyGH z{I|jkEJ. " ª% $" EQ. KL}% ^?MJK. %>6 jk. jkE!"«¬ 789y. .AB. E ~N O<RqP Q. %3 !"E£. R

(71) R^Q E?>%. S3%. ';x Y E034/` jk. #$13) jkERE?>. E ®¯789R E0Y. %MJKL}% ^SI|T% ?. N $©. @.AB<$#E0X. EQ /°±d F<Rq789 z. U>V IWXHYI. ¡²¢MF4 |}Q ,T#<M%. M $ hw xDZ. {Zw 3%3 I|J. ax. KL}% : ; [[x$. xDZ<=8³¥ ´#$N. RS UV£¤ . \ %$# ]Z%ÎW. $%>6. GH Q_è5 w Eabc R#. {I| de. # ?. M_TEJKf% N 3%4. ῏. ῎. Uµs6^ ¶A¦$ N". *t§¨·¸¹o©ª«¢¬$" U34«®»¼¯. Vol. 18. No. 4. 2008. 21.

(72) 22 . Vol. 18. No. 4 2008.. Hong Kong. England (UK). Susanna, K. P. Lau, et al. JCM 44: 3031ῌ3034. Claire A. Martin, et al. JMCR1: 40. 37 male. 43 female. 67 male. 2007. 2006. 2006. 2008. Year. Intravenous drug user. Cervix cancer. Multiple myeloma. Larynx cancer. Underlying disease. Mixed Bacteroides sp. Fusobacterium sp.. Mixed Unclear. Acute proctitisa (mucosa) Abscessus of injection insertion site. Mixed Oral flora. Mixed P. melaninogenica. Infection type copathogens. Abscessus of root portion of the tooth. Abscessus of cervix. Portal of entry. PIPC/TAZ Metronidazole PCG. 16S rRNA gene. CFPMAMK. PZFX CZOP. Treatment. 16S rRNA gene. 16S rRNA gene. 16S rRNA gene. Identification. Cure. ND. Cure. Death. Outcome. by radiation therapy; ND: no data; PZFX: pazufloxacin; CZOP: cefozopran; CFPM: cefepime; AMK: amikacin; PIPC/TAZ: piperacillin/tazobactam; PCG: benzylpenicillin.. Belgium. Detry, G., et al. Anaerobe 12: 160ῌ162. 60 male. Age Sex.

(73) . a. Japan. Country. Present study. Author. 4 Solobacterium moorei

(74) . 242 !"#$%.

(75) Solobacterium moorei RO 1 S ῍. ῌ 1). 2). 3). 4). 5). 6). 7). Kageyama, A., Y. Benno. 2000. Phylogenetic and phenotypic characterization of some Eubacterium-like isolates from human feces: Description of Solobacterium moorei gen. nov., sp. nov. Microbiol. Immunol. 44: 223ῌ227. Kazor, C. E., P. M. Mitchell, A. M. Lee, et al. 2003. Diversity of bacterial populations on the tongue dorsa of patients with halitosis and healthy patients. J. Clin. Microbiol. 41: 558ῌ 563. Haraszthy, V. I., J. J. Zambon, P. K. Sreenivasan, et al. 2007. Identification of oral bacterial species associated with halitosis. J. Am. Dent. Assoc. 138(8): 1113ῌ1120. Detry, G., D. Pierard, K. Vandoorslaer, et al. 2006. Septicemia due to Solobacterium moorei in a patient with multiple myeloma. Anaerobe 12: 160ῌ162. Susanna, K. P. Lau, J. L. Teng, K. W. Leung, et al. 2006. Bacteremia caused by Solobacterium moorei in a patientwith acute proctitis and carcinoma of the cervix. J. Clin. Microbiol. 44: 3031ῌ3034. Claire, A. Martin, Rohan S. Wijesurendra, Colin D. R. Borland, et al. 2007. Femoral vein thrombophlebitis and septic pulmonary embolism due to a mixed anaerobic infection including Solobacterium moorei: A case report. J. Med., Case Reports 1: 40. Wade, W. G., J. Downes, D. Dymock, et al. 1999. The family Coriobacteriaceae: reclassification of Eubacterium exiguum (Poco et al., 1996) and Peptostreptococcus heliotrinreducens (Lanigan, 1976) as Slackia exigua gen. nov., comb. nov. and Slackia heliotrinireducens gen. nov., comb. nov., and Eubacterium lentum (Prevot 1938) as. 243. Eggerthella lenta gen. nov., comb. nov. IJSB 49: 595ῌ600. 8) Eija Ko ¨no ¨nen, William G. Wade. 2007. Propionibacterium, Lactobacillus, Actinomyces, and Other Non-Spore-Forming Anaerobic GramPositive Rods. p. 872ῌ888, In: Manual of Clinical Microbiology, 9th ed. (P. R. Murray, E. J. Baron, M. A. Pfaller, et al. ed.), American Society for Microbiology, Washington, D.C. 9) Adriana Mosca, Paula Summanen, Sydney M. Finegold, et al. 1998. Cellular Fatty Acid Composition, Soluble-Protein Profile, and Antimicrobial Resistance Pattern of Eubacterium lentum. J. Clin. Microbiol. 36: 752ῌ755. 10)

(76)

(77) 2007 !"

(78)

(79) 2007 # 1 $ %& 3. '()*+,-./01 %&23 (5) 456 p. 10ῌ 12. 11) Bernard J. Moncla, Sharon L. Hillier. 2003. Peptostreptococcus, Propionibacterium, Lactobacillus, Actinomyces, and Other Non-SporeForming Anaerobic Gram-Positive Bacteria. p. 857ῌ889, In: Manual of Clinical Microbiology, 8th ed. (P. R. Murray, E. J. Baron, M. A. Pfaller, et al. ed.), American Society for Microbiology, Washington, D.C. 12) 789: 2006 ;< =>?@ABC D@EBD@FG HI &JK 80: 76ῌ83. 13)

(80)

(81) 2007 !"

(82)

(83) 2007 # 2 $ LM 2. EN@OP p. 61ῌ 63.. TU'(VWX&JK. Vol. 18. No. 4. 2008. 23.

(84) . 244. .

(85) . . Solobacterium moorei as a Cause of Sepsis in a Patient with Larynx Cancer: A First Case Report in Japan and Characterization of the Isolate Sanae Mori,1) Tomohisa Watari,1) Atushi Yasuda,1) Sachiko Miura,1) Takashi Ogaya,1) Munehiro Hatanaka,1) Kiyofumi Ohkusu2) 1) 2). Department of Clinical Laboratory, Kitami Red Cross Hospital Department of Microbiology, Gifu University Graduate School of Medicine. Herein we report the first Japanese case of sepsis caused by Solobacterium moorei, an anaerobic, non-sporulated Gram-positive bacillus in a patient with terminal-stage laryngeal cancer. A 60-year-old male was admitted to our hospital with high fever and fatigue. He had a long-lasting medical history and had a subcutaneous neck abscess. A set of blood culture was obtained with the BACTEC Aerobic/92F and Anaerobic/93F resin bottles. After 2 days, Gram-variable polymorphic rods and Prevotella melaninogenica grew from only the anaerobic culture vial. The RapID ANA system indicated that the Gram-variable polymorphic rod was 91.3 likely to be Eggerthella lenta. The API 20A system also showed that it was 94.2 likely to be E. lenta. However, we hesitated to identify it as E. lenta due to the discrepancies between results of our biochemical tests and of those reported in the literature. We therefore performed PCR amplification and DNA sequencing of the 16S rRNA gene of the isolate. A sequence of 1450 bp was found to be 99.6 homologous to the S. moorei type strain sequence (AY044915), indicating that the isolate was a strain of S. moorei, not E. lenta. To further characterize the isolate, we compared it with E. lenta strain (ATCC43055). It was found that they share the same phenotypical characteristics, except the isolate was negative for the catalase and the nitrate reduction tests, and positive for the a-glucosidase test. Thus, it is likely that S. moorei and E. lenta would be di#erentiated by these three reactions in clinical microbiology laboratory.. 24 . !"#$%&' Vol. 18. No. 4. 2008..

(86)